Very rare cases of blood clots linked to the Oxford-AstraZeneca COVID-19 vaccine are well-known and have been publicly recognized since 2021
The Oxford-AstraZeneca COVID-19 vaccine was one of the few tools available to reduce the risk of serious illness and death at the initial stages of the COVID-19 pandemic. The vaccine underwent rigorous testing to ensure it was safe and effective. In 2021, a rare but serious condition involving blood clots with low platelet level—known as thrombosis with thrombocytopenia—was associated with the vaccine. However, the chance that this condition will occur after vaccination is very low, and the benefits of vaccination outweigh this small risk.